Literature DB >> 18083218

Use of gene expression profiles to stage concurrent endometrioid tumors of the endometrium and ovary.

Alfred Guirguis1, Esther Elishaev, Sung-Hee Oh, George C Tseng, Kristin Zorn, Julie A DeLoia.   

Abstract

OBJECTIVE: The objectives of this study were to determine whether there are distinct gene expression profiles for endometrial and ovarian endometrioid carcinomas and to create a statistical model using these profiles to predict their organ of origin.
METHODS: Expression profiles of seven stage I, grades 1 and 2, endometrioid endometrial carcinomas and seven stage I ovarian endometrioid carcinomas were analyzed as the training set. The test set included seven advanced endometrial carcinomas and nine dual primary endometrial and ovarian primary tumors of endometrioid histology. Unsupervised hierarchical clustering, multidimensional scaling (MDS) and predictive analysis of microarrays (PAM) were used to analyze the data.
RESULTS: We identified 163 differentially expressed (DE) genes between endometrial and ovarian tumors. Both unsupervised hierarchical clustering and multidimensional scaling showed clear separation of the two groups. Pathway analysis of the 163 DE genes revealed significant biological differences between the two groups, which included metabolic and biosynthetic pathways. Further classification analysis on the training data using predictive analysis of microarray generated a 119-gene predictive model with 100% cross-validation accuracy. When the 119-gene model was applied to the test set of 16 samples, we found concordance in 11/16 samples and discordance in 5/16 samples with the pathologic classification.
CONCLUSION: We conclude that, although similar in histologic appearance, endometrioid carcinomas of the ovary and endometrium have distinct gene expression patterns. A larger test set is needed to prospectively evaluate this prediction model further.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18083218     DOI: 10.1016/j.ygyno.2007.10.008

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

1.  The clinical significance of isocitrate dehydrogenase 2 in esophageal squamous cell carcinoma.

Authors:  Xuan Chen; Wenzhe Xu; Cong Wang; Fang Liu; Shanghui Guan; Yi Sun; Xintong Wang; Dianzheng An; Zhihua Wen; Pengxiang Chen; Yufeng Cheng
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

2.  Over-expression of nicotinamide phosphoribosyltransferase in ovarian cancers.

Authors:  Rodney E Shackelford; Marilyn M Bui; Domenico Coppola; Ardeshir Hakam
Journal:  Int J Clin Exp Pathol       Date:  2010-06-12

3.  Differential analysis of ovarian and endometrial cancers identifies a methylator phenotype.

Authors:  Diana L Kolbe; Julie A DeLoia; Patricia Porter-Gill; Mary Strange; Hanna M Petrykowska; Alfred Guirguis; Thomas C Krivak; Lawrence C Brody; Laura Elnitski
Journal:  PLoS One       Date:  2012-03-05       Impact factor: 3.240

4.  Serine Biosynthesis Is a Metabolic Vulnerability in IDH2-Driven Breast Cancer Progression.

Authors:  Georgina D Barnabas; Joo Sang Lee; Tamar Shami; Michal Harel; Lir Beck; Michael Selitrennik; Livnat Jerby-Arnon; Neta Erez; Eytan Ruppin; Tamar Geiger
Journal:  Cancer Res       Date:  2021-01-26       Impact factor: 13.312

5.  Argininosuccinate lyase is a metabolic vulnerability in breast development and cancer.

Authors:  Sigurdur Trausti Karvelsson; Qiong Wang; Bylgja Hilmarsdottir; Arnar Sigurdsson; Siver Andreas Moestue; Gunhild Mari Mælandsmo; Skarphedinn Halldorsson; Steinn Gudmundsson; Ottar Rolfsson
Journal:  NPJ Syst Biol Appl       Date:  2021-09-17

6.  Altered expression levels of IDH2 are involved in the development of colon cancer.

Authors:  Qiang Lv; Shenyang Xing; Zhenxiao Li; Jianhua Li; Pengtao Gong; Xiaofang Xu; LE Chang; Xiaoxia Jin; Feng Gao; Wei Li; Guocai Zhang; Ju Yang; Xichen Zhang
Journal:  Exp Ther Med       Date:  2012-08-20       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.